Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.47 |
| ▸ | RXRA | P19793 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.37 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472521 | 0.92 | NR3C2 (0.47) | NR3C2RXRANR1H2NR1H3CNR1 | |
| SCHEMBL3471439 | 0.83 | RXRA (0.51) | NR3C2RXRANR1H2NR1H3SLC16A3 | |
| SCHEMBL3478472 | 0.82 | RXRA (0.57) | NR3C2RXRANR1H2NR1H3PTGS1 | |
| SCHEMBL3474265 | 0.82 | RXRA (0.50) | NR3C2RXRANR1H2NR1H3SLC16A3 | |
| SCHEMBL3473982 | 0.81 | NR3C2 (0.47) | NR3C2RXRANR1H2NR1H3SLC16A3 | |
| SCHEMBL3474985 | 0.79 | RXRA (0.49) | NR3C2RXRANR1H2NR1H3SLC16A3 | |
| SCHEMBL3471829 | 0.78 | CHRNB2 (0.52) | NR3C2RXRANR1H2NR1H3CNR1 | |
| SCHEMBL3472674 | 0.78 | RXRA (0.49) | NR3C2RXRANR1H2NR1H3DRD2 | |
| SCHEMBL3474534 | 0.78 | RXRA (0.50) | NR3C2RXRANR1H2NR1H3DRD2 | |
| SCHEMBL3474545 | 0.77 | CHRNB2 (0.51) | NR3C2RXRANR1H2NR1H3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | NR3C2 189/4885RXRA 18/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.